Embecta Corp
NASDAQ:EMBC

Watchlist Manager
Embecta Corp Logo
Embecta Corp
NASDAQ:EMBC
Watchlist
Price: 12.33 USD 0.33% Market Closed
Market Cap: 721.4m USD

Net Margin

8.8%
Current
Improving
by 1.8%
vs 3-y average of 7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
8.8%
=
Net Income
$95.4m
/
Revenue
$1.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
8.8%
=
Net Income
$95.4m
/
Revenue
$1.1B

Peer Comparison

Country Company Market Cap Net
Margin
US
Embecta Corp
NASDAQ:EMBC
721.3m USD
Loading...
JP
Hoya Corp
TSE:7741
8.5T JPY
Loading...
CH
Alcon AG
SIX:ALC
32.2B CHF
Loading...
US
Medline Inc
NASDAQ:MDLN
35.1B USD
Loading...
DK
Coloplast A/S
CSE:COLO B
123.4B DKK
Loading...
US
Align Technology Inc
NASDAQ:ALGN
12.2B USD
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
44.7B CNY
Loading...
UK
ConvaTec Group PLC
LSE:CTEC
4.7B GBP
Loading...
CA
Bausch + Lomb Corp
NYSE:BLCO
6.1B USD
Loading...
CH
Ypsomed Holding AG
SIX:YPSN
4.5B CHF
Loading...
US
Merit Medical Systems Inc
NASDAQ:MMSI
4.9B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in the United States of America
Percentile
64th
Based on 15 072 companies
64th percentile
8.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Embecta Corp
Glance View

Embecta Corp. emerges as a notable player in the medical technology landscape, carved out as an independent entity after parting ways from Becton, Dickinson and Company. The separation was driven by a vision to concentrate efforts more precisely on the specialized field of diabetes management. Embecta inherits a rich heritage of innovation and expertise, focusing on the development and distribution of advanced medical devices designed to assist individuals in managing diabetes. Their primary offering revolves around insulin delivery systems, which are critical for the day-to-day management of diabetes by patients worldwide. Embecta’s capabilities are further augmented by their robust research and development wing, which relentlessly pursues advancements in technology to improve patient outcomes and enhance user experience. The company’s business model hinges on a combination of product sales and the establishment of lasting relationships with healthcare providers and patients. By ensuring a steady pipeline of disposable products and innovative technologies, Embecta not only generates recurring revenue through its insulin delivery solutions but also positions itself as a leader in the field of diabetic care. Their strategy encompasses a strong distribution network that reaches global markets, leveraging partnerships, acquisitions, and direct sales strategies to expand their footprint. With an eye on the future, Embecta is keenly aware of the growing prevalence of diabetes globally and continues to innovate and adapt, ensuring that their products meet the evolving needs of their end-users.

EMBC Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
8.8%
=
Net Income
$95.4m
/
Revenue
$1.1B
What is Embecta Corp's current Net Margin?

The current Net Margin for Embecta Corp is 8.8%, which is above its 3-year median of 7%.

How has Net Margin changed over time?

Over the last 3 years, Embecta Corp’s Net Margin has decreased from 19.8% to 8.8%. During this period, it reached a low of 4.2% on Jun 30, 2023 and a high of 19.8% on Sep 30, 2022.

Back to Top